Beyond R-CHOP: New Frontiers in Lymphoma Treatment at ASH 2024
Even the cars stand out in San Diego
After writing of some trials and tribulations in solid tumours earlier this week (see review of the Janux TRACTR here), it was rather nice to return to my old stamping ground of hematologic malignancies and feel soothed by both the familiar and also incoming novel approaches for a variety of different conditions.
It is exactly twenty five years since the initial phase 1 data for STI-571 (now known as imatinib or Gleevec) were first presented in an ASH Plenary. 31 out of 31 advanced CML patients responded and Dr Brian Druker received an outstanding ovation at the end of his presentation. It was the kind of stuff that gave you goosebumps – despite the freezing cold hangar.
This is the kind of thing hematologists and companies alike live for; it’s what gets you jumping out of bed in the morning to help make a difference to the lives of cancer patients.
At ASH this year there are some encouraging data on early stage trials coming out in several hematologic malignancies, which kept me occupied and fascinated for most of the first day of the meeting. There’ll be another detailed write up of one of these areas tomorrow morning, while a different condition offered a raft of choices across single agent therapy and combinations alike.
Here we highlight what to watch out for – both positive and negative – on five agents with encouraging early data, which caught out attention yesterday. They include bispecific T cell engagers and cell therapies – what’s not to like?
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers